Novel Humanitarian Aid Program: The Glivec International Patient Assistance Program-Lessons Learned From Providing Access to Breakthrough Targeted Oncology Treatment in Low- and Middle-Income Countries

Novel Humanitarian Aid Program: The Glivec International Patient Assistance Program-Lessons Learned From Providing Access to Breakthrough Targeted Oncology Treatment in Low- and Middle-Income Countries

Item

http://www.wikidata.org/entity/Q38386664

Q38386664

about

A pharmacovigilance system for treatment access and medical donation programs: The Max Foundation experience

P2860

Q57930017-ED51F61C-DA8C-4733-A40D-B67CB98D6C2E

P2860

Novel Humanitarian Aid Program: The Glivec International Patient Assistance Program-Lessons Learned From Providing Access to Breakthrough Targeted Oncology Treatment in Low- and Middle-Income Countries

Item

http://www.wikidata.org/entity/Q38386664

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Novel Humanitarian Aid Program ...... w- and Middle-Income Countries

@en

type

Item

label

Novel Humanitarian Aid Program ...... w- and Middle-Income Countries

@en

prefLabel

Novel Humanitarian Aid Program ...... w- and Middle-Income Countries

@en

P1476

Novel Humanitarian Aid Program ...... w- and Middle-Income Countries

@en

P2093

David Epstein

http://www.w3.org/2001/XMLSchema#string

Pat Garcia-Gonzalez

http://www.w3.org/2001/XMLSchema#string

Paula Boultbee

http://www.w3.org/2001/XMLSchema#string

P2860

Expanding access to treatment for hepatitis C in resource-limited settings: lessons from HIV/AIDS

Effect of the Affordable Medicines Facility--malaria (AMFm) on the availability, price, and market share of quality-assured artemisinin-based combination therapies in seven countries: a before-and-after analysis of outlet survey data.

Benefits of global partnerships to facilitate access to medicines in developing countries: a multi-country analysis of patients and patient outcomes in GIPAP

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.

Improving access to care in low and middle-income countries: institutional factors related to enrollment and patient outcome in a cancer drug access program.

Expansion of cancer care and control in countries of low and middle income: a call to action.

Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.

Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.

Gleevec for the treatment of chronic myelogenous leukemia: US. Food and Drug Administration regulatory mechanisms, accelerated approval, and orphan drug status.

P304

37-45

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JGO.2015.000570

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-09-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28804770

http://www.w3.org/2001/XMLSchema#string

P932

5551649

http://www.w3.org/2001/XMLSchema#string

Novel Humanitarian Aid Program: The Glivec International Patient Assistance Program-Lessons Learned From Providing Access to Breakthrough Targeted Oncology Treatment in Low- and Middle-Income Countries

about

P2860

P2860

Novel Humanitarian Aid Program: The Glivec International Patient Assistance Program-Lessons Learned From Providing Access to Breakthrough Targeted Oncology Treatment in Low- and Middle-Income Countries

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932